Fig. 4.

The effect of celecoxib pretreatment on MAP and UV responses to intramedullary infusion of PF-3845 in C57BL/6J and FAAH KO mice. Control infusion periods with vehicle alone (C); 3.75, 7.5, 15, and 30 indicate dose rates for intramedullary PF-3845 infusion (nmol⋅kg⁻¹⋅min⁻¹). Period of celecoxib pretreatment (Cel; 15 mg/kg, iv), and posttreatment control infusion periods (P). A and B: C57BL/6J; C and D: FAAH KO. Data represent the mean ± the standard error of each group. *Significant difference vs. the respective C1 control group (P < 0.05; n = 5–7 per group). FAAH, fatty acid amide hydrolase; FAAH KO, FAAH homozygous knockout; kwt, kidney weight; MAP, mean arterial pressure; PF, PF-3845; PF-3845, N-3-pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidine carboxamide; UV, urine formation rate; n, sample size.